ELOVL2 and prostate cancer: CIDEC, CYP17A1, ELOVL2, and HACD1 were also associated with a variety of cancers including clear cell renal cell carcinoma, prostate cancer, neuroblastoma, and uveal melanoma and mainly participated in the metabolism of lipid storage droplets, promotion of de novo androgen biosynthesis, and regulation of fatty acid and inflammatory response (Yu et al., 2013; Xiao et al., 2018; Ding et al., 2019; Xu et al., 2019).